A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic Melanoma
Latest Information Update: 07 Jun 2025
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Amgen
Most Recent Events
- 09 Oct 2023 Status changed from not yet recruiting to recruiting.
- 28 Sep 2023 New trial record